Podcast with Ethan Perlstein of Perlara

How Perlara and Ethan Perlstein Are Pioneering the Future of Rare Disease Cures

In a recent podcast discussion with Maria Nimfuehr, Ethan Perlstein, the founder and CEO of Perlara, shared his journey from academia to becoming a pioneering biotech founder focused on finding treatments for rare diseases. Perlstein’s background in science and sociology influenced his innovative approach, leading him to launch Perlara as the world’s first Public Benefit Corporation (PBC) in the biotech space. Perlara aims to discover cures for rare genetic diseases using model organisms like yeast, worms, and flies—a method that has revolutionized drug discovery.

From Academia to Founding Perlara

Perlstein’s career took a significant turn in 2014 when he left academia. Dissatisfied with the traditional route of securing tenure, he sought an alternative way to practice science outside university labs. He realized that founding a biotech company would give him the control and freedom to focus on real-world problems, especially rare genetic diseases.

His inspiration for Perlara came from meeting a mother whose daughters were suffering from a fatal genetic disease. Perlstein recalls how this encounter sparked the idea of creating a business centered around partnerships with patient families, giving them a platform to contribute to and participate in the scientific process.

Collaborative Science with Families at the Core

Perlstein’s vision is built on the belief that families of patients with rare diseases are “DIY scientists”. He emphasizes how parents become deeply knowledgeable about their child’s disease, making them ideal collaborators in the search for cures. Perlara’s groundbreaking model uses N of 1 trials—personalized studies focusing on a single patient—to test potential treatments. By starting with one patient and expanding the trials to others, Perlstein calls this approach “one to N”, emphasizing the scalability of his method.

Perlara’s Success with Maggie’s Pearl

One of Perlara’s most notable projects is Maggie’s Pearl, a collaborative effort between Perlara, the Mayo Clinic, and the family of Maggie, a young girl with PMM2, a glycosylation disorder. Through their research, Perlara identified a drug previously approved in Japan for diabetes and repurposed it for treating Maggie’s condition. The results were promising, with notable improvements in Maggie’s motor functions.

This success story exemplifies the power of drug repurposing in rare diseases. Perlstein believes that many existing drugs have multiple uses and that repurposing them can lead to life-changing treatments for patients who otherwise have limited options.

Innovating with Model Organisms

Perlara’s use of simple organisms like yeast, worms, and flies as disease models sets it apart from traditional biotech companies that primarily rely on mice for preclinical trials. According to Perlstein, these simpler models share ancient biological processes with humans, making them ideal for quickly testing potential treatments. Yeast and worms are used to simulate human diseases and screen for drug candidates, cutting costs and speeding up the discovery process.

The Future of Rare Disease Research and Beyond

Perlstein’s vision goes beyond finding treatments for rare diseases. He sees opportunities for this research to play a role in longevity studies, where findings from metabolic diseases could inform studies on extending human lifespan. With emerging interest in Web3 technology, Perlstein is also exploring ways to decentralize the funding process through crowd investing and blockchain.

This decentralized model would allow more communities to finance medical research, reducing the burden on individual families. By giving patients and families a stake in the scientific process, Perlstein hopes to reshape the future of rare disease research.

Conclusion

Ethan Perlstein’s approach to collaborative science, where patient families become active partners, and his N of 1 trials methodology, are paving the way for a new era in rare disease research. Perlara’s work has already changed lives, and as it continues to grow, it promises to bring further breakthroughs not only in treating rare diseases but potentially in expanding the frontiers of longevity science.

Perlstein’s journey highlights a fundamental shift in the biotech world, where patient-led innovation and community-driven research could redefine how we tackle some of the most challenging medical issues of our time.